Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera.

ABSTRACT:

Introduction

Ruxolitinib is approved for the treatment of polycythemia vera (PV) with hydroxyurea resistance or intolerance. Approval was based on the phase III RESPONSE trial, which demonstrated efficacy in a highly selected patient population.

Materials and methods

To characterize the tolerability and outcomes of ruxolitinib outside of a clinical trial, we performed a multi-center retrospective analysis of patients with PV treated with ruxolitinib at 11 participating sites across the United States. Outcomes of interest included change in phlebotomy requirements after starting ruxolitinib and spleen response, as these were included in the primary composite outcome in the RESPONSE trial.

Results

One hundred twenty-six patients met eligibility criteria, and the median

SUBMITTER: Coltoff A 

PROVIDER: S-EPMC8900057 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature